Drug Search Results

Dezamizumab

Alternative Names: dezamizumab, gsk2398852
Latest Update: 2022-07-09
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: PTX2 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dezamizumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Amyloidosis

Phase 1: Cardiomyopathies|Amyloidosis

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
NCT03044353	P2	Terminated	Amyloidosis	2019-01-03	52%
NCT03044353	P2	Terminated	Amyloidosis	2019-01-03	52%
2016-000276-23	P2	Completed	Amyloidosis	2019-01-03
NCT03417830	P1	Terminated	Amyloidosis\|Cardiomyopathies	2018-07-20	22%
NCT01777243	P1	Completed	Amyloidosis	2015-12-22

Recent News Events

Date	Type	Title
07/09/2022	PubMed	An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.
02/13/2022	PubMed	Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
10/01/2021	PubMed	Novel methods to determine complement activation in human serum induced by the complex of Dezamizumab and serum amyloid P.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions